CONCLUSIONS:
Some current HbA 1c methods show clinically significant interferences with samples containing HbE or HbD traits. To avoid reporting of inaccurate results, ion-exchange chromatograms must be carefully examined to identify possible interference from these Hb variants. For some methods, manufacturers' instructions do not provide adequate information for making correct decisions about reporting results.
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Glycohemoglobin (GHB), 8 reported as hemoglobin (Hb) A 1c , is a marker of long-term glycemic control in patients with diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study demonstrated conclusively that risks for complications are directly related to glycemic control, as measured by HbA 1c (1, 2 ) . Many diabetes organizations worldwide recommend specific HbA 1c targets in terms of DCCT/United Kingdom Prospective Diabetes Study HbA 1c . The National Glycohemoglobin Standardization Program was established to standardize GHB/HbA 1c results so that clinical laboratory results are comparable to those reported by the DCCT. However, the accuracy of several HbA 1c methods can be adversely affected by the presence of Hb variants (3 ) , and the National Glycohemoglobin Standardization Program does not include evaluation of interferences as part of the certification program. The most common Hb variants worldwide are HbS, HbE, HbC, and HbD. Unlike HbS and HbC traits, for which most of the commonly used HbA 1c methods have already been, and continue to be, evaluated (4 -6 ) few data are available on the accuracy of HbA 1c measurement in the presence of HbE or HbD traits. Therefore we evaluated the effects of HbE and HbD trait on 23 commercial GHB methods using the Primus boronate affinity HPLC assay (ultra 2 ) as the comparison method.
HbE contains a substitution of lysine for glutamic acid at position 26 of the ␤-globin chain. HbE is the second most prevalent Hb variant worldwide and is found primarily in people from Southeast Asia; prevalence is 30%-40% in some parts of Thailand, Cambodia, and Laos (7 ). Owing to an influx of immigrants from Southeast Asia in recent years, HbE is now encountered quite commonly in the US. HbD Punjab (also called HbD Los Angeles), hereafter referred to as HbD, contains a substitution of glutamine for glutamic acid at position 121 of the ␤-globin chain. HbD Punjab is found most commonly in the Punjab region of India (2%-3% prevalence in Sikhs in Punjab) and is also encountered in the US (8 ) .
Materials and Methods

SAMPLES
This study was approved by the ethics review committee at DynaLIFE DX in Edmonton, Canada, where the samples originated. Whole blood samples from individuals homozygous for HbA (n ϭ 49) and for HbE or HbD trait (HbAE, HbAD) (n ϭ 42 for each trait) were collected in EDTA-containing tubes. After routine clinical testing had been completed, the samples previously identified as having HbD Punjab or HbE traits by use of the Bio-Rad Beta Thalassemia HPLC system and Sebia Hydrasys electrophoresis at both alkaline and acid pH were shipped on cold packs to the Diabetes Diagnostic Laboratory at the University of Missouri (Columbia, MO). Several small aliquots were made from each sample and stored at Ϫ70°C until they were shipped on dry ice to various sites for analysis. method. An overall test of coincidence of 2 least-squares linear regression lines was performed using SAS software (SAS Institute) to determine whether the presence of HbE or HbD trait caused a statistically significant difference (P Ͻ 0.01) in results relative to the comparison method. Deming regression analysis was performed to determine whether the presence of HbE or HbD trait produced a clinically significant effect on HbA 1c results. Given recommendations by the American Diabetes Association of an upper reference limit of 6%, the American Diabetes Association goal of 7%, and the DCCT conventional group mean HbA 1c of approximately 9%, we chose HbA 1c evaluation limits of 6% and 9%. After correcting for possible calibration bias by comparing results from the homozygous HbA sample group, we evaluated method bias due to the presence of HbE or HbD trait, with a clinically significant difference being Ͼ10% relative bias at 6% and 9% HbA 1c (i.e., 0.6% at 6% HbA 1c and 0.9% at 9% HbA 1c ).
Results
Box plots for each group of samples and for each method, with indications of both statistical and clinical significance are shown in Fig. 1 . Although statistically significant differences were found in more than half of the methods tested, only 5 of 23 and 3 of 23 showed clinically significant interferences for HbE and HbD traits, respectively. Table 1 lists the differences at 6% and 9% HbA 1c for each variant and for each method. There were no clinically significant differences seen for either HbE or HbD traits for any of the immunoassay methods tested, or for the PDQ, Afinion, Enzymatic method, CE method, Variant II NU, or D-10 short and extended programs. In addition, there were no clinically significant differences seen for HbD trait for the 2.2 Plus, G7, or G8. There were no clinically significant differences seen for the HbE trait for the Variant and the HA-8160 TP mode. The Variant II Turbo showed clinically significant interference from both HbE and HbD traits, as did the Menarini HA8160 diabetes mode. The HA-8160 TP mode does not quantify HbA 1c in the presence of HbD trait.
In addition to the actual bias in the HbA 1c result caused by the presence of these variant Hbs, it is important that any unacceptable results are detected and not reported. Fortunately, we found that results from samples with HbE and HbD traits do not show interference with HbA 1c measurement by the immunoassay, enzymatic, and boronate affinity methods that were evaluated, because Hb variants are not discernable with these methods. It is not surprising that HbE and HbD traits do not interfere with immunoassay methods, given that the amino acid substitutions are far from the N-terminus of the ␤ chain where HbA 1c glycation and antibody binding occur. These results were consistent with a previous report (12 ) .
In cases in which ion-exchange methods show clinically significant interferences, it is important to know whether following manufacturer instructions would prevent the reporting of unacceptable results. Unfortunately, some manufacturer instructions for acceptance of results by ion-exchange methods are not clearly stated, and some manufacturers do not provide sample chromatograms. Examples of chromatograms from such methods with clinically unacceptable results are shown in Supplemental Figs. 1-4 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/issue8.
For the Tosoh 2.2 Plus, the manufacturer states that it is acceptable to report an "Hb Var" peak after HbA 0 ; this would include a peak for the HbD trait. Our data confirm the acceptability of these manufacturer instructions. If there is an unidentifiable peak before the A 0 peak (e.g., P00, P01), the result is not reportable; this is the case for HbE trait, and indeed our data show nonreportable results for HbAE. For the Tosoh G7, the manufacturer instructions say that any abnormal peak before HbA 0 will cause erroneous HbA 1c results; this includes a peak for the HbE trait. Our results confirm that such abnormal peaks are indeed not reportable. Because the HbD peak appears after the HbA 0 peak, results showing this peak should be reportable; our study data confirm this. For the G8, the manufacturer instructions state that the HbA 1c is reportable for HbD trait because the variant peak and P00 peaks elute after the A0 and their sum is not Ͼ55%. HbAE is stated to be nonreportable since there is an extra peak appearing between the A 1c and A 0 peak. HbE and D trait chromatograms appear in the G8 instruction manual. The present results confirm the manufacturer's instructions and show that HbD trait results are accurate, whereas HbE trait results are not.
For the Variant no information is provided by the manufacturer about whether or not HbE or HbD trait chromatograms are acceptable or certain chromatographic features are unacceptable. The present data show that HbE trait chromatograms are indistinguishable from those with HbAA; fortunately the results from the present study also show that results from these chromatograms are acceptable. Our study data indicate that results for HbD trait are not acceptable for the Variant, results that are consistent with a previous report (12 ) . Although not stated in the instruction manual for the Variant method, HbD trait samples showed chromatograms with "unknown" peaks, one of which separates between the A 1c and A 0 peaks (see Supplemental Fig. 1 a Deming regression analysis was performed using the Ultra2 as the comparison method. The mean difference (%) of each of the other methods at clinical decision cutoffs of 6% and 9% were calculated for each Hb trait. To correct for intermethod calibration differences, the mean difference for homozygous HbA samples was subtracted from that calculated for samples containing HbE or HbD trait. b Methods used are listed in alphabetical order by manufacturer. c Clinically significant (Ͼ0.6% or Ͼ0.9% HbA 1c at 6% and 9% HbA 1c , respectively) differences were found. d Calculated from only those samples for which an HbA 1c result was quantified.
showing HbE and HbD traits are acceptable and shows typical chromatograms from samples with HbE and HbD trait with both HbE and HbD appearing in the "E,D" window. Our results confirm that results showing HbE and HbD traits are acceptable for the Variant II NU. The instruction manual for the Variant II Turbo does not mention samples with HbE or HbD traits. However, all HbE and HbD trait chromatograms include a peak in the "variant window" that appears on the printed chromatogram as a split A 0 peak (see Supplemental Fig. 2 in the online Data Supplement). In the present study, we found these results to be unacceptable for the Variant II Turbo. For the Bio-Rad D-10 short program, the manufacturer makes no claim for HbA 1c results with HbE and HbD trait samples. For the short program there is a peak that elutes after the HbA 0 peak in the "Variant-window" for both HbD and HbE traits. For the D-10 extended program, samples containing HbD have a large "unknown" peak separated after HbA 2 . HbE appears to be separated in the HbA 2 window, causing a very high HbA 2 value (up to approximately 30%). We found that results were within clinically acceptable limits (Ϯ10% of the HbA 1c at 6% and 9%) for both the short and extended program and that results were actually better with the short program.
For the Menarini HA-8160, no statement about HbE or HbD traits is included in the instruction manual. In the diabetes mode, samples containing HbD trait show an extra peak in the "S/C Window" (see Supplemental None of the immunoassay, enzymatic, or boronate affinity methods we investigated showed clinically significant interference, whereas some of the ion-exchange HPLC methods showed interference from HbE or HbD traits, or both. All of the ion-exchange methods that demonstrated interferences from HbE and/or HbD trait, with the exception of the Variant II Turbo, produced artificially low results. Reporting of such results could lead to undertreatment of hyperglycemia, with concomitant increased risks for complications. In the case of the Variant II Turbo, the artificially increased results seen in the presence of both HbE and HbD traits could result in overly aggressive treatment that could increase risk of hypoglycemia. As mentioned previously, ion-exchange chromatograms must be carefully examined to identify possible interference from these Hb variants so that inaccurate results are not reported (13 ) . In most (but not all) cases, reporting of inaccurate results can be avoided if manufacturer instructions are followed carefully. For some methods, however, manufacturer instructions alone do not provide sufficient information for making the correct decision about reporting results. Laboratories should be aware of the limitations of their methods with respect to these variants and indicate this information on reports to physicians. Physicians should consider the possibility of interference from an Hb variant if a patient's HbA 1c result is significantly different from what is expected on the basis results of blood glucose self-monitoring and/or other diagnostic test results or clinical symptoms.
In addition to interference of these variant Hbs on the actual measurement method for HbA 1c , biological factors that may affect HbA 1c concentrations must also be considered. For example, altered erythrocyte lifespan or a variant Hb that glycates at a rate different from that of HbA could result in artificially low or high HbA 1c . Reports suggest that erythrocyte lifespan is normal in individuals with HbD trait and homozygous HbE (8, 14 ) . Given that the amino acid substitutions in HbD and HbE are both far from the primary site of Hb glycation (the N-terminus of the ␤ chain), it seems unlikely that either variant would demonstrate glycation rates that are significantly different from that of HbA. Nonetheless, further studies are needed to verify this assumption. 
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